Please assess the completion status of the following clinical trial:

Trial Title: A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Selected Inclusion Criteria:~Parts A \& B (COMPLETED ENROLLMENT):~* Healthy male or female~* 18-55 years of age, inclusive~* At least 50 kg in weight~* BMI: 18.0-30.0 kg/m2, inclusive~Part C (COMPLETED ENROLLMENT):~* Male or female with atopic dermatitis~* 18-65 years of age, inclusive~* BMI between 18.0 (inclusive) and \<40.0 kg/m2~* Body surface area (BSA) with AD involvement ≥10%~* Eczema Area and Severity Index (EASI) score ≥12~* Validated Investigator's Global Assessment (vIGA) ≥3~* History of inadequate response to treatment with topical medications, such as corticosteroids or calcineurin inhibitors, or patients for whom topical treatments are otherwise medically inadvisable~Selected Exclusion Criteria:~Parts A \& B (COMPLETED ENROLLMENT):~* Use of tobacco products within 60 days prior to drug administration~* History of alcohol abuse or drug addiction~* Positive drug and alcohol screen~* Participation in a drug study within 60 days prior to drug administration~* Donation or loss of more than 100 mL of blood within 60 days prior to drug administration.~* Donation or loss of more than 1.5 liters of blood (for male subjects) / more than 1.0 liters of blood (for female subjects) in the 10 months prior to drug administration.~Part C (COMPLETED ENROLLMENT):~* Any serious and/or uncontrolled medical condition~* History of alcohol abuse or drug addiction~* Positive drug and alcohol screen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- COMPLETED ENROLLMENT -- Single Dose Escalation Part A - active (Type: EXPERIMENTAL): Increasing doses of RPT193 will be administered to healthy volunteers
- COMPLETED ENROLLMENT -- Single Dose Escalation Part A - placebo (Type: PLACEBO_COMPARATOR): Matching placebo will be administered to healthy volunteers
- COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - active (Type: EXPERIMENTAL): Increasing doses of RPT193 will be administered once/day for 7 days to healthy volunteers
- COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - placebo (Type: PLACEBO_COMPARATOR): Matching placebo will be administered once/day for 7 days to healthy volunteers
- COMPLETED ENROLLMENT -- Expansion Part C - active (Type: EXPERIMENTAL): RPT193 will be administered daily for 28 days to patients with atopic dermatitis
- COMPLETED ENROLLMENT -- Expansion Part C - placebo (Type: PLACEBO_COMPARATOR): Matching placebo will be administered daily for 28 days to patients with atopic dermatitis

Based on this trial design, predict the completion outcome and termination type (if applicable).